InveniAI will collaborate with PRISM BioLab to build a pipeline of novel therapeutic candidates addressing diseases in the gut associated with the dysfunction of the gut-brain-axis and inflammasome dysregulation.
InveniAI will use its proprietary AlphaMeld® platform to identify and validate relevant novel targets that will be used to develop transformative therapies for gut-related diseases. PRISM BioLab will use its proprietary platform to design small-molecule candidates against targets validated by InveniAI. InveniAI will pursue human proof of concept for all candidate drugs.